Clinical trial / 2022
Afternoon intake of nicotinamide mononucleotide improved lower limb function and reduced drowsiness in older adults.
A randomized, double-blind, placebo-controlled study evaluated the effects of 250 mg daily nicotinamide mononucleotide (NMN) taken in the morning (AM) or afternoon (PM) for 12 weeks among 108 older adults across four groups. Five-times sit-to-stand (5-STS) improved post-intervention in all groups, while drowsiness improved at mid- and post-intervention in the NMN_PM and Placebo_PM groups. The NMN_PM group exhibited the largest effect sizes for 5-STS (d = 0.72) and drowsiness (d = 0.64). Overall, afternoon NMN intake effectively improved lower limb function and reduced drowsiness.
- Study type
- Randomized, double-blind, placebo-controlled study
- Who was studied
- 108 older Japanese adults
- What was measured
- Sleep quality, fatigue, and physical performance measures
THE PAPER
Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study.
Kim M, Seol J, Sato T, Fukamizu Y, Sakurai T, Okura T. Nutrients, 2022.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.